AustraliaTuberculosis profile
Population  2016 24 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.048 (0.047–0.048) 0.2 (0.2–0.2)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.02 (0.01–0.03)
Incidence  (includes HIV+TB) 1.5 (1.3–1.7) 6.1 (5.2–7.1)
Incidence (HIV+TB only) 0.029 (0.025–0.034) 0.12 (0.1–0.14)
Incidence (MDR/RR-TB)** 0.063 (0.04–0.086) 0.26 (0.16–0.36)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.063 (0.054–0.073) 0.64 (0.54–0.73) 0.7 (0.59–0.8)
Males 0.072 (0.061–0.082) 0.7 (0.6–0.81) 0.77 (0.66–0.89)
Total 0.14 (0.11–0.16) 1.3 (1.1–1.5) 1.5 (1.3–1.7)
TB case notifications, 2016  
Total cases notified 1 376
Total new and relapse 1 376
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 83%
          - % pulmonary 63%
          - % bacteriologically confirmed among pulmonary 90%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 93% (81–110)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.04 (0.03–0.04)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 21 2%
          - on antiretroviral therapy    
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  40
(26–55)
Estimated % of TB cases with MDR/RR-TB 3.6% (2.2–5.4) 24% (9.4–45)  
% notified tested for rifampicin resistance 74% 71% 1 016
MDR/RR-TB cases tested for resistance to second-line drugs   25
Laboratory-confirmed cases MDR/RR-TB: 30, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 29, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 73% 1 244
Previously treated cases, excluding relapse, registered in 2015   0
HIV-positive TB cases registered in 2015 43% 21
MDR/RR-TB cases started on second-line treatment in 2014 61% 18
XDR-TB cases started on second-line treatment in 2014 100% 1
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-20 Data: www.who.int/tb/data